News Updates
More Articles
- The Pitfalls and Promise of Cell and Gene Therapy Development: A Time for Concerted Action
- “Not Just Checking a Box”: A Call to Rethink Patient Involvement in the EU
- From Cells to Animals and Back Again: The Shifting Landscape of Cancer Efficacy and Safety Models
- Addressing Inequity: Embedding Inclusion and Diversity in UK Clinical Trials
- The Next AI Revolution: Computer System Validation
Regulatory Utilization of Real-World Data and Real-World Evidence in Japan: Pharmaceuticals and Medical Devices Agency (PMDA) Chief Executive Perspective
In cases when a randomized controlled trial cannot be conducted because of the limited patient population for rare diseases or other reasons, the PMDA has been making good use of RWD/RWE for regulatory decision-making.